Chemotherapy
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
15
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Barrett's Esophagus
Conditions
Barrett's Esophagus, Esophageal Cancer
Trial Timeline
Jan 1, 2015 → Jan 1, 2027
NCT ID
NCT02634645About Chemotherapy
Chemotherapy is a pre-clinical stage product being developed by Pacific Biosciences for Barrett's Esophagus. The current trial status is recruiting. This product is registered under clinical trial identifier NCT02634645. Target conditions include Barrett's Esophagus, Esophageal Cancer.
Hype Score Breakdown
Clinical
5
Activity
2
Company
2
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05704621 | Phase 2 | Recruiting |
| NCT02634645 | Pre-clinical | Recruiting |
Competing Products
3 competing products in Barrett's Esophagus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Esomeprazole + Aspirin + Rofecoxib | AstraZeneca | Approved | 85 |
| Esomeprazole + Lansoprazole | AstraZeneca | Approved | 85 |
| Esomeprazole Magnesium | AstraZeneca | Approved | 85 |